Evotec Extends Medicinal Chemistry Collaboration with Ono Pharmaceutical

16-Oct-2009 - Japan

Evotec AG announced that it has extended its current research collaboration with Ono Pharmaceutical Co., Ltd. (Ono) and initiated a new discovery collaboration. Under the contract extension Evotec will provide integrated drug discovery activities, including high throughput screening, medicinal chemistry and in vitro pharmacology to discover novel, small molecular weight compounds active against an ion channel target selected by Ono. Ono will access Evotec’s ion channel drug discovery platform and expertise and Evotec will receive research funding and milestone payments.

Evotec and Ono have collaborated since March 2008 identifying novel inhibitors for a protease target. Within this collaboration Evotec provides protein crystallography, medicinal chemistry, biology and ADMET services to Ono with the aim of progressing a compound towards clinical development.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Revolutionary new insights into blood vessel formation in cancer - Research opens new avenue for cancer therapy

Antisense Pharma Obtains IND for Clinical Studies in the USA - The American Department of Health, the FDA, agrees to the use of trabedersen for high-grade glioma (malignant brain tumor)

Novel antibiotics in the fight against antimicrobial resistance - SANTERO announces a €8 million Series A funding round led by Newton Biocapital

Novel antibiotics in the fight against antimicrobial resistance - SANTERO announces a €8 million Series A funding round led by Newton Biocapital

KÖTTERMANN finds an investor

Combination Therapy against Cancer - Synergistic anticancer therapy with two cell killer agent systems in one nanocapsule

Combination Therapy against Cancer - Synergistic anticancer therapy with two cell killer agent systems in one nanocapsule

QUANTRO Therapeutics receives important Austrian research funding to further develop its platform for the discovery of novel cancer therapies - Austrian Research Promotion Agency FFG awards funding to QUANTRO to accelerate the next development phase of the company's proprietary research platform

QUANTRO Therapeutics receives important Austrian research funding to further develop its platform for the discovery of novel cancer therapies - Austrian Research Promotion Agency FFG awards funding to QUANTRO to accelerate the next development phase of the company's proprietary research platform

Max-Planck-Institut für Entwicklungsbiologie - Tübingen, Germany

Cell Cultivated Leather - VitroLabs raises $46 million to build and scale the world's first pilot production of cell cultivated leather

Cell Cultivated Leather - VitroLabs raises $46 million to build and scale the world's first pilot production of cell cultivated leather

Summit's lead drug candidate enters phase II clinical trials - Candidate targets sialorrhoea, a symptom of Parkinson's disease

Novartis enters into agreement for exclusive US and Canadian rights to Fanapt, an FDA-approved oral therapy for schizophrenia

UK start-up aims to advance pioneering NK cell therapy - NK:IO raises £1.2M, bringing total Seed funding to £5.1M

UK start-up aims to advance pioneering NK cell therapy - NK:IO raises £1.2M, bringing total Seed funding to £5.1M

Biovitrum acquires promising anti-obesity drug leads from BioFocus